hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06337058, orgStudyIdInfo id: KSUHULYAKAMALAK001, briefTitle: Motivational Interviews With Women Experiencing Sexual Dysfunction During Menopause Period, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-06-15, primaryCompletionDateStruct date: 2021-06-15, completionDateStruct date: 2022-12-15, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Hülya KAMALAK, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the effect of motivational interviews with women who experience sexual dysfunction during menopause on sexual quality of life and self-efficacy.The population of the study consisted of menopausal women who applied to the gynecology outpatient clinic of Kahramanmaraş Sütçü İmam University Health Practice and Research Hospital. It was calculated as 164 women (82 experimental, 82 control).In data collection, 'Personal Information Form (EK- )', 'Arizona Sexual Experiences Scale (ACYÖ) (EK- )', 'Sexual Quality of Life Scale-Female (SIQQ-F) (EK-)' and 'Sexual Self-Efficacy Scale' (Annex- )' was used., conditionsModule conditions: Sexual Dysfunction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 164, type: ACTUAL, armsInterventionsModule interventions name: Experimental group (motivational interview), outcomesModule primaryOutcomes measure: Arizona Sexual Experiences Scale - Female Version Questionnaire (ASEX-F), primaryOutcomes measure: Arizona Sexual Experiences Scale - Female Version Questionnaire (ASEX-F), primaryOutcomes measure: Sexual Quality of Life-Female Questionnaire (SQOL-F), primaryOutcomes measure: Sexual Quality of Life-Female Questionnaire (SQOL-F), primaryOutcomes measure: Sexual Self-Efficacy Scale (SSES), primaryOutcomes measure: Sexual Self-Efficacy Scale (SSES), eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kahramanmaras Sutçu Imam University, city: Kahramanmaraş, country: Turkey, geoPoint lat: 37.5847, lon: 36.92641, hasResults: False
protocolSection identificationModule nctId: NCT06337032, orgStudyIdInfo id: GS-US-380-6684, briefTitle: A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2034-03, completionDateStruct date: 2034-03, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Gilead Sciences, class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.The primary objectives of this study are as follows:* To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.* To evaluate the safety of the study drug(s) in participants with HIV-1., conditionsModule conditions: HIV-1-infection, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: F/TAF (High Dose Tablet), interventions name: F/TAF (Low Dose Tablet), interventions name: F/TAF (Lowest Dose Tablet), interventions name: F/TAF (High Dose TOS), interventions name: F/TAF (Low Dose TOS), interventions name: F/TAF (Lowest Dose TOS), interventions name: E/C/F/TAF, interventions name: E/C/F/TAF (Low Dose), interventions name: Cobicistat (High Dose), interventions name: Cobicistat (Low Dose), interventions name: Cobicistat (TOS), interventions name: B/F/TAF (High Dose), interventions name: B/F/TAF (Low Dose), interventions name: B/F/TAF (High Dose TOS), interventions name: B/F/TAF (Low Dose TOS), interventions name: B/F/TAF (Lowest Dose TOS), interventions name: 3rd ARV Agent, interventions name: Nucleos(t)ide reverse transcriptase inhibitors (NRTI), interventions name: ATV, interventions name: DRV, interventions name: Lopinavir Boosted with ritonavir (LPV/r), outcomesModule primaryOutcomes measure: Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study, secondaryOutcomes measure: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs), eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337006, orgStudyIdInfo id: SÜKAEK 2023/14/1, briefTitle: Laryngeal Mask Airway Failure in Pediatric Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-15, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2024-05-15, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Samsun University, class: OTHER, descriptionModule briefSummary: There are a significant number of studies identifying risk factors for misplacement of LMAs. However, despite objective data indicating that tracheal intubation is performed inappropriately, such as air leaks, high air pressures, insufficient lung ventilation and single lung ventilation, which are easily identified after tracheal intubation, there are no objective data to define the misplacement of LMAs, which are increasingly used especially in short surgical procedures.The aim of the study was to describe unsuccessful LMA placement in pediatric patients with objective data., conditionsModule conditions: Airway Management, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Placement of the laryngeal mask airway, outcomesModule primaryOutcomes measure: Evaluation of the success of placement of the laryngeal mask airway, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Samsun University, status: RECRUITING, city: Samsun, state: Canik, zip: 55090, country: Turkey, contacts name: OZGUR KOMURCU, 1, role: CONTACT, phone: 90 505 5273180, email: zgrkom@gmail.com, contacts name: Hatice SELCUK KUSDERCİ, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.27976, lon: 36.3361, hasResults: False
protocolSection identificationModule nctId: NCT06336993, orgStudyIdInfo id: liuxianguiji, briefTitle: Evaluation of Clinical Efficacy of Herbal Compound in the Treatment of NSLBP, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2023-06-16, completionDateStruct date: 2023-12-15, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Zhejiang Provincial Tongde Hospital, class: OTHER, descriptionModule briefSummary: The aim of this randomized controlled trial was to explore the clinical efficacy and safety of HXTL in the treatment of NSLBP based on TCM principles and to compare the clinical outcomes of different syndromes of NSLBP with celecoxib.In this study, 80 patients with NSLBP were recruited and randomly grouped to use TCM compound and celeoxib respectively for intervention. The pain status and lumbar function use scale of patients were scored before intervention, 1 week, 2 weeks and 3 weeks after intervention, and the adverse reactions of patients after medication were recorded, and the clinical efficacy of the two groups of patients was compared finally., conditionsModule conditions: Low Back Pain, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 71, type: ACTUAL, armsInterventionsModule interventions name: herbal compound, interventions name: Celecoxib, outcomesModule primaryOutcomes measure: Visual Analogue Scale, primaryOutcomes measure: Oswestry disability index, primaryOutcomes measure: Japanese Orthopaedic Association Scores, otherOutcomes measure: the adverse reactions of digestive or other system, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongde Hospital, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06336967, orgStudyIdInfo id: 855282, briefTitle: Testing a Wellness App for First Responders, Military Personnel and Veterans, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: University of Pennsylvania, class: OTHER, collaborators name: Nlyten Corp, descriptionModule briefSummary: The purpose of the research study is to trial a smart phone application, the GUIDE App, to better understand its impact on social connectedness, personal growth and mental health/wellness among first responders, soldiers, and veterans. The research team will also investigate workplace metrics (e.g., engagement and burnout), implementation outcomes and technical merit. The investigators plan to run a three-armed randomized waitlist pilot feasibility trial with up to 150 participants., conditionsModule conditions: Mental Health Wellness, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: GUIDE, outcomesModule primaryOutcomes measure: PERMA-Profiler Overall Wellbeing Score, primaryOutcomes measure: Patient Health Questionnaire for depression symptoms (PHQ-8), primaryOutcomes measure: Generalized Anxiety Disorder (GAD-7), primaryOutcomes measure: WHO Well-being Index (WHO-5), primaryOutcomes measure: Personal Wellbeing Score (PWS), primaryOutcomes measure: Difficulties in Emotion Regulation Scale Short Form (DERS-SF), secondaryOutcomes measure: Positive Emotion (Positive emotion subscale of the PERMA-Profiler), secondaryOutcomes measure: Social Connectedness (Engagement and Relationship subscales of PERMA-Profiler), secondaryOutcomes measure: Social Connectedness (Number of posts/comments in the app), secondaryOutcomes measure: Personal Growth (Meaning and Accomplishment subscales of the PERMA-Profiler), secondaryOutcomes measure: Personal Growth (Total GUIDE lessons and courses completed), secondaryOutcomes measure: Utrecht Work Engagement Scale (UWES-17), secondaryOutcomes measure: Maslach Burnout Inventory (MBI), secondaryOutcomes measure: Job Retention (Employment status), otherOutcomes measure: Feasibility of Intervention Measure (FIM), otherOutcomes measure: Acceptability of Intervention Measure (AIM), otherOutcomes measure: Intervention Appropriateness Measure (IAM), otherOutcomes measure: System Usability Scale (SUS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Pennsylvania, city: Philadelphia, state: Pennsylvania, zip: 19146, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06336954, orgStudyIdInfo id: MA-NSCLC-#-037, briefTitle: Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital of Xi'an Jiaotong University, class: OTHER, descriptionModule briefSummary: This prospective, single-arm trial explores the efficacy of Adibelimab monoclonal antibody combined with Famitinib and chemotherapy in treating locally advanced or metastatic NSCLC patients with negative driver genes who have progressed after PD-1 monoclonal antibody and chemotherapy treatment. The study focuses on assessing progression-free survival (PFS) in 40 participants. Key objectives include evaluating PFS and understanding the progression patterns post-first-line immunotherapy, with an interest in whether switching from PD-1 to PD-L1 inhibitors can overcome immune resistance., conditionsModule conditions: Non Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Adibelimab, outcomesModule primaryOutcomes measure: Progression-free survival time (PFS), secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Duration of Response, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Treatment-Related Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06336941, orgStudyIdInfo id: 32822, briefTitle: "Ultra-High Frequency intraOral UltraSonography of the TONgue" (HOUSTON), acronym: HOUSTON, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-06-07, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2030-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Pisa, class: OTHER, descriptionModule briefSummary: Oral diseases are currently diagnosed by means of clinical examination and supported by surgical biopsy procedures. In particular, daily oral medicine practice is lacking the use of a routine diagnostic support to the visualization of anatomical structures located beyond the mucosal surface. Considering the growing interest in minimally invasive diagnosis, the possibility of having an imaging technique dedicated to the investigation of oral soft tissues and their alterations may be instrumental to support the clinical diagnosis. Therefore, attempts to introduce conventional ultrasonography (US) to the diagnostic work-up of pathological conditions of the head and neck have been done, exploiting the unique features of this technique in terms of limited invasive- ness, repeatability, and cost efficiency.In the literature, both extraoral and intraoral applications of US have been reported. Extraoral applications mainly focus on the characterization of oral and maxillofacial swellings of various origin, while intraoral applications mostly involve the study of malignant lesions in terms of tumor thickness and depth of invasion. The aim of the present protocol is to evaluate the role of intraoral ultra-high frequency ultrasonography in the study of oral mucosal lesions., conditionsModule conditions: Oral Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound, outcomesModule primaryOutcomes measure: Depth of invasion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Università di Pisa, status: RECRUITING, city: Pisa, zip: 56126, country: Italy, contacts name: Rossana Izzetti, DS, PhD, role: CONTACT, phone: +39050993037, email: rossana.izzetti@unipi.it, geoPoint lat: 43.70853, lon: 10.4036, hasResults: False
protocolSection identificationModule nctId: NCT06336928, orgStudyIdInfo id: 1B-23-6, secondaryIdInfos id: NCI-2024-01332, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 1B-23-6, type: OTHER, domain: USC / Norris Comprehensive Cancer Center, secondaryIdInfos id: P30CA014089, type: NIH, link: https://reporter.nih.gov/quickSearch/P30CA014089, briefTitle: A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2029-04-01, completionDateStruct date: 2030-04-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Southern California, class: OTHER, collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer., conditionsModule conditions: Breast Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 490, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Assess the sensitivity and specificity of LBx as a screening method for breast cancer, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Keck Medicine of USC Koreatown, city: Los Angeles, state: California, zip: 90020, country: United States, contacts name: Bomi Choi, role: CONTACT, phone: 323-865-0451, email: Bomi.Choi@med.usc.edu, contacts name: Anastasia Martynova, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, locations facility: Los Angeles General Medical Center, city: Los Angeles, state: California, zip: 90033, country: United States, contacts name: Kimberly Arieli, RN, role: CONTACT, phone: 323-865-0451, email: Kimberly.Arieli@med.usc.edu, contacts name: Anastasia Martynova, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, locations facility: USC / Norris Comprehensive Cancer Center, city: Los Angeles, state: California, zip: 90033, country: United States, contacts name: Kimberly Arieli, RN, role: CONTACT, phone: 323-865-0451, email: Kimberly.Arieli@med.usc.edu, contacts name: Anastasia Martynova, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, locations facility: USC Norris Oncology/Hematology-Newport Beach, city: Newport Beach, state: California, zip: 92663, country: United States, contacts name: Kristy Massopust, role: CONTACT, phone: 949-474-5733, email: Massopust_K@med.usc.edu, contacts name: Anastasia Martynova, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.61891, lon: -117.92895, hasResults: False
protocolSection identificationModule nctId: NCT06336915, orgStudyIdInfo id: 121.NUR.2022.D, briefTitle: Physician-Nurse Dyad Rounding: A Collaborative Approach to Improve Unit-Level Metrics, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-03, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Methodist Health System, class: OTHER, descriptionModule briefSummary: The project will be implemented on one unit at a time until the co-rounding process has been implemented on each Medical-Surgical unit. This study will involve the geo-localized hospitalist on the designated unit and the nursing staff involved in clinical patient care, conditionsModule conditions: Wellness, Psychological, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Physician-Nurse Dyad Rounding, outcomesModule primaryOutcomes measure: Difference in percentage of discharged patients before 1400 (Mon-Fri) after project implementation compared to before implementation, secondaryOutcomes measure: Difference in Top Box Patient Satisfaction Scores and Doctor Domain, secondaryOutcomes measure: Difference in LOS of private hospitalist patients after project implementation compared to before implementation, secondaryOutcomes measure: Difference in collaboration and build positive relationships scores after project implementation compared to before implementation, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinical Research Institute at Methodist Health System, status: RECRUITING, city: Dallas, state: Texas, zip: 75203, country: United States, contacts name: Colette N Ndjom, MS, role: CONTACT, phone: 410-947-4681, phoneExt: 74681, email: ColetteNgoNdjom@mhd.com, contacts name: Loretta W Bedell, MPH, role: CONTACT, phone: 214-947-4680, phoneExt: 74680, email: lorettabedell@mhd.com, contacts name: Lauren Hoffman, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.78306, lon: -96.80667, locations facility: Methodist Dallas Medical Center, status: NOT_YET_RECRUITING, city: Dallas, state: Texas, zip: 75203, country: United States, contacts name: Colette N Ndjom, MS, role: CONTACT, phone: 214-947-4681, email: mhsirb@mhd.com, contacts name: Loretta W Bedell, MPH, role: CONTACT, phone: 217-947-4680, email: mhsirb@mhd.com, contacts name: Lauren Hoffman, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06336889, orgStudyIdInfo id: 092.TRA.2018.D, briefTitle: Pelvic Angioembolization: A Prospective Multi-Institutional Study (Data From All Campuses Will be Used), statusModule overallStatus: RECRUITING, startDateStruct date: 2017-10-26, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Methodist Health System, class: OTHER, descriptionModule briefSummary: The investigator's propose a multicenter prospective observational study to investigate the use of embolization in patients with negative angiogram and to ascertain the optimal level of treatment when the angiogram is positive; non-selective vs. selective embolization., conditionsModule conditions: Pelvic Hemorrhage, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Pelvic Angioembolization, outcomesModule primaryOutcomes measure: Mortality outcome, primaryOutcomes measure: transfusion requirements, primaryOutcomes measure: thromboembolic events, secondaryOutcomes measure: Patient demographics(age, sex), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Methodist Dallas Medical Center, status: RECRUITING, city: Dallas, state: Texas, zip: 75201, country: United States, contacts name: Jennifer Burris, MD, role: CONTACT, phone: 214-947-1280, email: clinicalresearch@mhd.com, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False